Showing 1,098 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C

Editor's pick
Business Wire
10 January 2011
Hepatitis C treatment

Merck Beats Vertex to FDA Hep C Filing

Editor's pick
The Street
7 January 2011
Hepatitis C treatment

Pharmasset Reports Positive Results from its HCV Clinical Programs

Editor's pick
Pharmasset
6 January 2011
Hepatitis C treatment

Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients

Editor's pick
PR Newswire
5 January 2011
Hepatitis C treatment

Hepatitis Experts Create Roadmap for Accelerating the Development of Targeted Therapies for Hepatitis C Virus

Editor's pick
Forum for Collaborative HIV Research
15 December 2010
Hepatitis C treatment

European recommendations issued on acute hepatitis C infection in patients with HIV

News
15 December 2010
Hepatitis C treatment

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Editor's pick
Medical News Today
18 November 2010
Hepatitis C transmission & prevention

Hepatitis C still increasing in German gay men with HIV, reinfection common

News
12 November 2010
Hepatitis C treatment

Early analysis finds good outcomes with once-daily dosing of HCV protease inhibitor TMC435

Editor's pick
HIVandhepatitis.com
8 November 2010
Hepatitis C treatment

From podium to practice: Updates in HCV treatment

Editor's pick
Clinical Care Options (registration required)
8 November 2010
Clinical trials

Hepatitis C researcher arrested on insider trading charges

Editor's pick
New York Times
3 November 2010
Hepatitis C treatment

AASLD: Anti-HCV drug boosts response rates

Editor's pick
MedPage Today
3 November 2010
Hepatitis C treatment

New tool developed to predict success of hepatitis C therapy in HIV/HCV-co-infected patients

News
2 November 2010
Hepatitis C treatment

AASLD: Successful HCV Tx cuts deaths post-transplant

Editor's pick
MedPage Today
1 November 2010
Hepatitis C treatment

Gilead presents phase IIa data for HCV therapy at The Liver Meeting 2010

Editor's pick
The Medical News
1 November 2010
Hepatitis C treatment

Longer Hep C Treatment Improves Response in People Coinfected With HIV

Editor's pick
AIDSMeds
1 November 2010
Hepatitis C treatment

Black patients fare well on Vertex hepatitis C drug

Editor's pick
Reuters
31 October 2010
New & experimental hepatitis C treatment

Investigational drug for hepatitis C boceprevir achieved significantly higher sustained virologic response rates compared to control

Editor's pick
Digital Journal
31 October 2010
Hepatitis C treatment

Bristol-Myers, Gilead seek AIDS cocktail success in hepatitis C

Editor's pick
Bloomberg
30 October 2010
Hepatitis C treatment

High hepatitis C mortality and low clearance rates in HIV/HCV-co-infected patients in France

News
29 October 2010
Hepatitis C treatment

Hepatitis C drug pipeline analysis and market forecasts to 2016

Editor's pick
Press release
27 October 2010
Hepatitis C treatment

Vertex Pharmaceuticals highlights progress in hepatitis C drug development

Editor's pick
Vertex
27 October 2010
Hepatitis C transmission & prevention

Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells

Editor's pick
Eurekalert Medicine & Health
10 October 2010
Hepatitis C treatment

NICE’s publishes 200th guidance to better tackle Hepatitis C

Editor's pick
Pharma Times
27 September 2010